AMP Capital Investors Ltd reduced its position in shares of Seattle Genetics, Inc. (NASDAQ:SGEN) by 36.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,933 shares of the biotechnology company’s stock after selling 19,100 shares during the quarter. AMP Capital Investors Ltd’s holdings in Seattle Genetics were worth $1,762,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in SGEN. American International Group Inc. purchased a new position in shares of Seattle Genetics during the 4th quarter valued at $121,000. Quantbot Technologies LP grew its holdings in shares of Seattle Genetics by 116.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 1,428 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Seattle Genetics during the 3rd quarter valued at $203,000. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Seattle Genetics during the 3rd quarter valued at $208,000. Finally, Trexquant Investment LP purchased a new position in shares of Seattle Genetics during the 3rd quarter valued at $226,000. 93.09% of the stock is currently owned by institutional investors.
Shares of SGEN stock opened at $50.95 on Friday. Seattle Genetics, Inc. has a fifty-two week low of $45.31 and a fifty-two week high of $71.32. The stock has a market cap of $8,548.33, a PE ratio of -57.90 and a beta of 1.96.
In other Seattle Genetics news, insider Vaughn B. Himes sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $58.12, for a total transaction of $290,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Clay B. Siegall sold 18,832 shares of the company’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $57.32, for a total transaction of $1,079,450.24. The disclosure for this sale can be found here. Insiders have sold 71,953 shares of company stock valued at $3,833,188 over the last 90 days. Corporate insiders own 34.70% of the company’s stock.
SGEN has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $74.00 price target (up from $72.00) on shares of Seattle Genetics in a report on Wednesday, February 7th. HC Wainwright reiterated a “buy” rating on shares of Seattle Genetics in a report on Wednesday, February 7th. Royal Bank of Canada reiterated a “buy” rating and issued a $73.00 price objective on shares of Seattle Genetics in a report on Tuesday. TheStreet cut shares of Seattle Genetics from a “c-” rating to a “d+” rating in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Seattle Genetics in a report on Tuesday, January 9th. Ten investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $64.63.
TRADEMARK VIOLATION NOTICE: “Seattle Genetics, Inc. (SGEN) Holdings Cut by AMP Capital Investors Ltd” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3294978/seattle-genetics-inc-sgen-holdings-cut-by-amp-capital-investors-ltd.html.
Seattle Genetics Profile
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seattle Genetics, Inc. (NASDAQ:SGEN).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.